Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754886 | 0.75 | ALDH1A1 (0.32) | — | |
| SCHEMBL33377367 | 0.75 | CA1 (0.36) | NPC1LMNARAB9A | |
| SCHEMBL8372471 | 0.59 | TTR (0.41) | NPC1LMNARAB9A | |
| SCHEMBL2649168 | 0.59 | LMNA (0.58) | NPC1LMNARAB9A | |
| SCHEMBL22129686 | 0.58 | CA1 (0.48) | NPC1LMNARAB9A | |
| SCHEMBL6285317 | 0.58 | TTR (0.32) | — | |
| SCHEMBL7755458 | 0.58 | — | — | |
| SCHEMBL18939806 | 0.57 | ACHE (0.48) | NPC1LMNARAB9A | |
| SCHEMBL29096395 | 0.57 | CA9 (0.42) | LMNA | |
| SCHEMBL12578987 | 0.56 | RAB9A (0.41) | NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | BACE1, BACE2, PSEN1 | NPC1 155/4885LMNA 752/4885RAB9A 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.